1. Home
  2. SCAGW vs JAGX Comparison

SCAGW vs JAGX Comparison

Compare SCAGW & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCAGW
  • JAGX
  • Stock Information
  • Founded
  • SCAGW N/A
  • JAGX 2013
  • Country
  • SCAGW China
  • JAGX United States
  • Employees
  • SCAGW N/A
  • JAGX N/A
  • Industry
  • SCAGW Construction/Ag Equipment/Trucks
  • JAGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCAGW Consumer Discretionary
  • JAGX Health Care
  • Exchange
  • SCAGW Nasdaq
  • JAGX Nasdaq
  • Market Cap
  • SCAGW 4.0M
  • JAGX 3.5M
  • IPO Year
  • SCAGW N/A
  • JAGX N/A
  • Fundamental
  • Price
  • SCAGW $0.08
  • JAGX $2.63
  • Analyst Decision
  • SCAGW
  • JAGX Strong Buy
  • Analyst Count
  • SCAGW 0
  • JAGX 1
  • Target Price
  • SCAGW N/A
  • JAGX $60.00
  • AVG Volume (30 Days)
  • SCAGW N/A
  • JAGX 80.9K
  • Earning Date
  • SCAGW N/A
  • JAGX 08-12-2025
  • Dividend Yield
  • SCAGW N/A
  • JAGX N/A
  • EPS Growth
  • SCAGW N/A
  • JAGX N/A
  • EPS
  • SCAGW N/A
  • JAGX N/A
  • Revenue
  • SCAGW N/A
  • JAGX $11,552,000.00
  • Revenue This Year
  • SCAGW N/A
  • JAGX $22.41
  • Revenue Next Year
  • SCAGW N/A
  • JAGX $30.00
  • P/E Ratio
  • SCAGW N/A
  • JAGX N/A
  • Revenue Growth
  • SCAGW N/A
  • JAGX 13.93
  • 52 Week Low
  • SCAGW N/A
  • JAGX $2.43
  • 52 Week High
  • SCAGW N/A
  • JAGX $110.75
  • Technical
  • Relative Strength Index (RSI)
  • SCAGW N/A
  • JAGX 31.41
  • Support Level
  • SCAGW N/A
  • JAGX $2.53
  • Resistance Level
  • SCAGW N/A
  • JAGX $2.65
  • Average True Range (ATR)
  • SCAGW 0.00
  • JAGX 0.21
  • MACD
  • SCAGW 0.00
  • JAGX 0.12
  • Stochastic Oscillator
  • SCAGW 0.00
  • JAGX 22.99

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: